Corvus Pharmaceuticals executive buys 4,500 shares

Available on EDGAR 11/13/2026 - 05:55 PM EST Accepted by SEC EDGAR 11/13/2026 - 05:54 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. (CRVS) Chief Business Officer Jeffrey Arcara reported four direct purchases of common stock totaling 4,500 shares from November 11 through November 13, 2026. He purchased 3,000 shares at $11.4602 per share on November 11 and 497 shares at $11.1150 per share on November 12. On November 13, he purchased 503 shares at $10.3700 per share and 500 shares at $10.7087 per share. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 4,500 shares

Net Buy 4 txns

Insider Arcara Jeffrey

Role Chief Business Officer

Bought 4,500 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	503	$10.37	$5K
Purchase	Common Stock	500	$10.7087	$5K
Purchase	Common Stock	497	$11.115	$6K
Purchase	Common Stock	3,000	$11.4602	$34K

Holdings After Transaction: Common Stock — 4,500 shares (Direct)

Key Figures

Total shares purchased: 4,500 shares Purchase on November 11, 2026: 3,000 shares at $11.4602 per share Purchase on November 12, 2026: 497 shares at $11.1150 per share +2 more

5 metrics

Total shares purchased 4,500 shares Four direct purchases from November 11 through November 13, 2026

Purchase on November 11, 2026 3,000 shares at $11.4602 per share Direct common-stock purchase

Purchase on November 12, 2026 497 shares at $11.1150 per share Direct common-stock purchase

Purchase on November 13, 2026 503 shares at $10.3700 per share Direct common-stock purchase

Purchase on November 13, 2026 500 shares at $10.7087 per share Direct common-stock purchase

Key Terms

Rule 10b5-1 plan

1 terms

Rule 10b5-1 plan regulatory

"No Rule 10b5-1 plan is reported"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRVS shares did Jeffrey Arcara buy, and at what prices?

Jeffrey Arcara, Corvus Pharmaceuticals' Chief Business Officer, reported buying 4,500 shares in four direct purchases: 3,000 at $11.4602 per share on November 11, 497 at $11.1150 per share on November 12, and 503 at $10.3700 per share plus 500 at $10.7087 per share on November 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arcara Jeffrey

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2026		P		3,000	A	$11.4602	3,000	D
Common Stock	11/12/2026		P		497	A	$11.115	3,497	D
Common Stock	11/13/2026		P		503	A	$10.37	4,000	D
Common Stock	11/13/2026		P		500	A	$10.7087	4,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Leiv Lea, as Attorney-in-Fact for Jeffrey Arcara	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)